Nat Clin Pract Cardiovasc Med. 2006;3(6):290-291. A positive causal relationship between the concentration of LDL cholesterol and the future risk of cardiovascular events is one of the best-proven ...
Hosted on MSN
New pill shows 60 per cent LDL reduction in trials: Cardiologists break down if it reduces heart attack risk
High levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for cardiovascular disease, which continues to be one of the leading causes of illness and death globally. LDL-C can ...
A Prescription Drug User Fee Act target date of December 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...
Please provide your email address to receive an email when new articles are posted on . Spatz, an associate professor of cardiology and epidemiology at Yale University School of Medicine, discussed ...
BOSTON -- A PCSK9 inhibitor contributed extra LDL cholesterol lowering as an early add-on to standard high-intensity statins in the acute period of ST-segment elevation MI (STEMI), the small ...
Aim This study investigated the influence of depression status on lipid lowering therapy (LLT) prescribing and achievement of ...
Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% ...
The ability of niacin to influence LDL-P is under active investigation and it appears that the beneficial effects of niacin extend beyond the traditional evaluation of the 'lipid profile.' Taken ...
Cholesterol is widely recognized as a key risk factor for the development of atherosclerosis and cardiovascular disease (CVD), which remains a leading cause of morbidity and mortality worldwide 1.
Use of OTC dietary supplements is increasingly common, sometimes replacing guideline-recommended therapies. Rosuvastatin was associated with larger reductions in LDL-C compared with placebo, fish oil, ...
Lower may indeed be better, suggests a new analysis of the FOURIER trial addressing outcomes in patients whose LDL cholesterol was brought below 40 mg/dL. The findings, say investigators, support some ...
Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results